Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 0.9 kDa | Depends on exact fragment sequence and counterion |
| Amino acid sequence | LKKTETQ (commonly cited) | Short actin-binding motif from thymosin beta-4 |
| Common salt form | Acetate salt | Trifluoroacetate also reported in research material |
| Reconstitution solvent | Sterile water or buffer | Gentle mixing; avoid vigorous agitation |
| Solution storage | -20 °C or lower | Aliquot to avoid repeated freeze-thaw cycles |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
=== Overdose === There is limited information available on the acute toxicity of methocarbamol. Overdose is observed frequently in conjunction with CNS depressants such as alcohol or benzodiazepines and will have symptoms of nausea, drowsiness, blurred vision, hypotension, seizures, and coma. There are reported deaths with an overdose of methocarbamol alone or in the presence of other CNS depressants.
=== Rehabilitation === Professor Cathy Schnieder of International Service at American University noted that in 1989, blacks, representing 12-15% of all drug use in the United States, made up 41% of all arrests. That was a noted increase from 38% in 1988. Whites were 47% of those in state-funded treatment centers but fewer than 10% of those committed to prison.
Drew was born in 1904 into an African-American middle-class family in Washington, D.C. His father, Richard, was a carpet layer, and his mother, Nora Burrell, trained as a teacher. Drew and three (two sisters, one brother) of his four younger siblings (three sisters and one brother) grew up in Washington's largely middle-class and interracial Foggy Bottom neighborhood. From a young age Drew began work as a paperboy in his neighborhood, daily helping deliver over a thousand newspapers to his neighbors. Drew attended Washington's Dunbar High School which was well-known for its equality and opportunities for all, despite the racial climate at the time. From 1920 until his marriage in 1939, Drew's permanent address was in Arlington County, Virginia, although he graduated from Washington's Dunbar High School in 1922 and resided elsewhere during that period of time.
Sources: en.wikipedia.org
== Arthropathies and related disorders (710–719) == 710 Diffuse diseases of connective tissue 710.0 Systemic lupus erythematosus 710.2 Sjögren's syndrome 710.3 Dermatomyositis 710.4 Polymyositis 710.5 Eosinophilia myalgia syndrome 710.9 Connective tissue disease, unspec. 711 Arthropathy associated with infections 712 Crystal arthropathies 712.1 Chondrocalcinosis due to dicalcium phosphate crystals 712.2 Chondrocalcinosis due to pyrophosphate crystals 712.3 Chondrocalcinosis, cause unspecified pseudogout 712.8 Other specified crystal arthropathies 712.9 Unspecified crystal arthropathy 713 Arthropathy, endocrine disorders 713.1 Arthropathy, gastrointestinal conditions 714 Rheumatoid arthritis and other inflammatory polyarthropathies 714.0 Rheumatoid arthritis 714.3 Polyarticular juvenile rheumatoid arthritis 715 Osteoarthrosis and allied disorders 715.09 Osteoarthrosis, generalized, multiple sites 715.11 Osteoarthrosis, shoulder 715.14 Osteoarthrosis, hand 715.15 Osteoarthrosis, hip 715.16 Osteoarthrosis, knee 715.17 Osteoarthrosis, ankle/foot 715.9 Osteoarthrosis, unspec. 716 Other and unspecified arthropathies 716.1 Arthropathy, traumatic, unspec. 716.9 Arthropathy, unspec. 717 Internal derangement of knee 717.1 Derangement of anterior horn of medial meniscus 717.42 Derangement of lateral meniscus 717.7 Chondromalacia of patella 717.9 Derangement, internal, knee, unspec.
The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – is an assay for evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR. They are used to determine the clotting tendency of blood, in conditions such as the measure of warfarin dosage, liver damage (cirrhosis), and vitamin K status. PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X (Stuart–Prower factor). PT is often used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway and common pathway of coagulation.
=== Cycles related to the 3-hydroxypropionate cycle === A variant of the 3-hydroxypropionate cycle was found to operate in the aerobic extreme thermoacidophile archaeon Metallosphaera sedula. This pathway is called the 3-hydroxypropionate/4-hydroxybutyrate (3-HP/4-HB) cycle. Yet another variant of the 3-hydroxypropionate cycle is the dicarboxylate/4-hydroxybutyrate (DC/4-HB) cycle. It was discovered in anaerobic archaea. It was proposed in 2008 for the hyperthermophile archeon Ignicoccus hospitalis.
== Malignant neoplasm of digestive organs and peritoneum (150–159) == 150 Malignant neoplasm of esophagus 151 Malignant neoplasm of stomach 152 Malignant neoplasm of small intestine, including duodenum 153 Malignant neoplasm colon 154 Malignant neoplasm of rectum, rectosigmoid junction, and anus 155 Malignant neoplasm of liver and intrahepatic bile ducts 156 Malignant neoplasm of gallbladder and extrahepatic bile ducts 157 Malignant neoplasm of pancreas 158 Malignant neoplasm of retroperitoneum and peritoneum 159 Malignant neoplasm of other and ill-defined sites within the
Sources: en.wikipedia.org
Paul, Gregory S. (2002). Dinosaurs of the Air: The Evolution and Loss of Flight in Dinosaurs and Birds. Baltimore; London: Johns Hopkins University Press. ISBN 978-0-8018-6763-7. LCCN 2001000242. OCLC 1088130487.. Sternberg, Charles Mortram (1966) [Original edition published by E. Cloutier, printer to the King, 1946]. Canadian Dinosaurs. Geological Series. Vol. 54 (2nd ed.). Ottawa: National Museum of Canada. LCCN gs46000214. OCLC 1032865683. Stewart, Tabori & Chang (1997). The Humongous Book of Dinosaurs. New York: Stewart, Tabori & Chang. ISBN 978-1-55670-596-0. LCCN 97000398. OCLC 1037269801. University of Southampton (September 29, 2021). "Two New Species of Large Predatory Dinosaur with Crocodile-Like Skulls Discovered on Isle of Wight". SciTechDaily. Zhou, Zhonghe (October 2004). "The origin and early evolution of birds: discoveries, disputes, and perspectives from fossil evidence" (PDF). Naturwissenschaften. 91 (10). Berlin: Springer Science+Business Media: 455–471. Bibcode:2004NW.....91..455Z. doi:10.1007/s00114-004-0570-4. ISSN 0028-1042. PMID 15365634. S2CID 3329625. Archived from the original (PDF) on July 21, 2011. Retrieved November 6, 2019.
== Patent infringement lawsuit == In 2002, MDS (at that time owner of SCIEX) and joint venture partner Applied Biosystems, won a $52.6 million judgement against Micromass UK for infringement of U.S. Patent No. 4,963,736 that describes a method of ion focusing using RF fields and gas collisions.
== History == Although food engineering is a relatively recent and evolving field of study, it is based on long-established concepts and activities. The traditional focus of food engineering was preservation, which involved stabilizing and sterilizing foods, preventing spoilage, and preserving nutrients in food for prolonged periods of time. More specific traditional activities include food dehydration and concentration, protective packaging, canning and freeze-drying . The development of food technologies was greatly influenced and urged by wars and long voyages, including space missions, where long-lasting and nutritious foods were essential for survival. Other ancient activities include milling, storage, and fermentation processes. Although several traditional activities remain of concern and form the basis of today’s technologies and innovations, the focus of food engineering has recently shifted to food quality, safety, taste, health and sustainability.
Sources: en.wikipedia.org
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.
Reversed-phase liquid chromatography separates components and reports purity from peak area. Mass spectrometry confirms the molecular mass expected for the sequence. Additional approaches such as peptide mapping or amino acid analysis provide independent confirmation.
Reported percentages depend on the analytical method, the detection wavelength, and whether salts and water are counted. A value above ninety-five percent by chromatography does not by itself establish a correct sequence. Different suppliers also calculate purity against different reference standards.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.